| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581696 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 28 Pages |
Abstract
Insurance source at diagnosis has no impact on AML treatment outcomes. The consistency of our results with some, but not all, studies is probably driven primarily by access-to-care eligibility requirements among different states. Further efforts to better understand such disparities are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Samer A. Srour, Michael Machiorlatti, Namali T. Pierson, Usman Z. Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Vesely, Carla D. Kurkjian,